I am a
Home I AM A Search Login

Papers of the Week

2022 Mar 07

Clin Neurol Neurosurg


A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine.


Nandyala AS, Suri H, Dougherty CO, Ailani J
Clin Neurol Neurosurg. 2022 Mar 07; 215:107200.
PMID: 35286994.


Prior to the approval of erenumab, onabotulinum toxin A (onabot A) was the only Food and Drug Administration-approved chronic migraine preventive treatment. In this study, we assess the safety and efficacy of the combination of erenumab and onabot A for chronic migraine prevention.